| Drug | Class | Adult | Paediatric | Notes |
|---|---|---|---|---|
| Osimertinib[1] | Third-generation EGFR tyrosine kinase inhibitor | 80 mg PO once daily | — | First-line for EGFR exon 19 deletion or L858R; adjuvant in resected stage IB–IIIA EGFR+; CNS-active; QTc, ILD, cardiotoxicity monitoring |
| Pembrolizumab[1] | Anti-PD-1 monoclonal antibody | 200 mg IV every 3 weeks or 400 mg every 6 weeks × up to 2 years | — | Stage IV NSCLC with PD-L1 ≥50% as monotherapy; combine with chemotherapy regardless of PD-L1; immune-related adverse events (pneumonitis, colitis, endocrinopathies, hepatitis) |
| Cisplatin or carboplatin + pemetrexed (non-squamous)[1] | Platinum doublet chemotherapy | Cisplatin 75 mg/m² or carboplatin AUC 5–6 + pemetrexed 500 mg/m² IV every 3 weeks × 4–6 cycles, then maintenance pemetrexed | — | Standard chemotherapy backbone for NSCLC non-squamous; folic acid + B12 with pemetrexed; renal dose adjustment for cisplatin |
| Carboplatin + paclitaxel (squamous NSCLC) or + pembrolizumab[1] | Platinum doublet ± immunotherapy | Carboplatin AUC 5–6 + paclitaxel 175–200 mg/m² IV every 3 weeks × 4 cycles, then pembrolizumab maintenance | — | Squamous NSCLC; combine with pembrolizumab regardless of PD-L1; hypersensitivity, neuropathy |
| Cisplatin/carboplatin + etoposide (SCLC)[1] | Platinum doublet chemotherapy | Cisplatin 60–80 mg/m² or carboplatin AUC 5 + etoposide 100 mg/m² IV days 1–3 every 3 weeks × 4 cycles | — | Standard chemotherapy backbone for SCLC; combine with atezolizumab or durvalumab in extensive stage; concurrent thoracic radiotherapy in limited stage |
Diagnosis, biomarker-driven treatment of NSCLC and SCLC, immunotherapy, and palliative care for adults with lung cancer.